Premium
Targeting of the hNC16A collagen domain to dendritic cells induces tolerance to human type XVII collagen
Author(s) -
Ettinger Monika,
Gratz Iris K.,
Gruber Christina,
HauserKronberger Cornelia,
Johnson Theron S.,
Mahnke Karsten,
Thalhamer Josef,
Hintner Helmut,
PecklSchmid Doris,
Bauer Johann W.
Publication year - 2012
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/j.1600-0625.2012.01474.x
Subject(s) - cd8 , transgene , antigen , dendritic cell , antibody , transfection , immunology , in vivo , transplantation , biology , immune tolerance , microbiology and biotechnology , cancer research , medicine , cell culture , gene , genetics , biochemistry
Antibodies, specific to murine DEC205, can be used to target antigens to dendritic cells. The immunodominant domain of human type XVII collagen, hNC16A, was fused to this antibody (DEC‐hNC16A) and was administered as expression plasmid by gene gun transfection with the aim of inducing tolerance to human type XVII collagen in a skin transplantation model. Mice transfected with DEC‐hNC16A were challenged with skin grafts from transgenic mice engineered to express human type XVII collagen. Graft survival was either prolonged or grafts were accepted infinitely (33% and 16%, respectively) upon treatment with DEC‐hNC16A while 100% of grafts were rejected in untreated controls. Graft acceptance was associated with the absence of a CD4+ infiltrate and a dense CD8+ T‐cell infiltrate and was not strictly dependent on antibody production. Our results show that DEC‐hNC16A targets dendritic cells in vivo leading to prolonged survival of transgenic skin grafts. This indicates that DEC205‐targeting may be used for the induction of tolerance to skin antigens, which would increase the chances of successful skin gene therapy of epidermolysis bullosa patients.